TY - JOUR
T1 - Mesenchymal stem cells in the treatment of articular cartilage degeneration
T2 - New biological insights for an old-timer cell
AU - Colombini, Alessandra
AU - Perucca Orfei, Carlotta
AU - Kouroupis, Dimitrios
AU - Ragni, Enrico
AU - De Luca, Paola
AU - ViganÒ, Marco
AU - Correa, Diego
AU - de Girolamo, Laura
N1 - Funding Information:
This article was supported by the Italian Ministry of Health, “Ricerca Corrente” and the Soffer Family Foundation. The authors declare no conflict of interest.
Publisher Copyright:
© 2019 International Society for Cell and Gene Therapy
PY - 2019/12
Y1 - 2019/12
N2 - Osteoarthritis (OA) is a debilitating, degenerative joint disease characterized by progressive destruction of articular cartilage. Given the poor repair capacity of articular cartilage and the associated local destructive immune/inflammatory responses involving all joint structures, OA frequently ends up as a “whole joint failure” requiring prosthetic replacement. Current pharmacological efforts, belatedly started, mainly aim at symptomatic pain relief, underscoring the need for novel therapeutic schemes designed to modify the course of the disease. Mesenchymal stem cell (MSC)–based therapy has gained significant interest, sparking the design of multiple trials proving safety while providing promising preliminary efficacy results. MSCs possess ‘medicinal signaling cell’ properties related to their immunomodulatory and anti-inflammatory effects, which induce the establishment of a pro-regenerative microenvironment at the injured tissue. Those trophic effects are paralleled by the long-established chondroprogenitor capacity that can be harnessed to ex vivo fabricate engineered constructs to repair damaged articular cartilage. The present review focuses on these two aspects of the use of MSCs for articular cartilage damage, namely, cell therapy and tissue engineering, providing information on their use criteria, advancements, challenges and strategies to overcome them.
AB - Osteoarthritis (OA) is a debilitating, degenerative joint disease characterized by progressive destruction of articular cartilage. Given the poor repair capacity of articular cartilage and the associated local destructive immune/inflammatory responses involving all joint structures, OA frequently ends up as a “whole joint failure” requiring prosthetic replacement. Current pharmacological efforts, belatedly started, mainly aim at symptomatic pain relief, underscoring the need for novel therapeutic schemes designed to modify the course of the disease. Mesenchymal stem cell (MSC)–based therapy has gained significant interest, sparking the design of multiple trials proving safety while providing promising preliminary efficacy results. MSCs possess ‘medicinal signaling cell’ properties related to their immunomodulatory and anti-inflammatory effects, which induce the establishment of a pro-regenerative microenvironment at the injured tissue. Those trophic effects are paralleled by the long-established chondroprogenitor capacity that can be harnessed to ex vivo fabricate engineered constructs to repair damaged articular cartilage. The present review focuses on these two aspects of the use of MSCs for articular cartilage damage, namely, cell therapy and tissue engineering, providing information on their use criteria, advancements, challenges and strategies to overcome them.
KW - articular cartilage degeneration
KW - cell priming
KW - extracellular vesicles
KW - mesenchymal stem cells
KW - paracrine activity
KW - tissue resident progenitors
UR - http://www.scopus.com/inward/record.url?scp=85076283085&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076283085&partnerID=8YFLogxK
U2 - 10.1016/j.jcyt.2019.10.004
DO - 10.1016/j.jcyt.2019.10.004
M3 - Review article
C2 - 31784241
AN - SCOPUS:85076283085
VL - 21
SP - 1179
EP - 1197
JO - Cytotherapy
JF - Cytotherapy
SN - 1465-3249
IS - 12
ER -